A Phase 1 interventional study of Ceftobiprole medocaril in Bacterial Infections, sponsored by Basilea Pharmaceutica. Terminated at 14 sites in 6 countries. Open to participants aged Up to 3 Months. Per ClinicalTrials.gov, last updated 2023-06-05.
Sponsored by Basilea Pharmaceutica · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 181 studies in Bacterial Infections with a site in United States — 12 open to participants now, 15 under way, 2 of them phase 3. Bacterial Infections · United States.
Among the 181 studies in Bacterial Infections with a site in United States, this one is the 136th largest by enrollment of the 151 interventional ones that give a count, is one of 13 that started in 2016, is one of 66 in phase 1, and was the 94th registered.
585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.
Browse Bacterial Infections studies →12 of the 181 studies in Bacterial Infections with a site in United States are open now. Recruiting first, the newest first:
Nanopath, Inc · Sites in United States
Ages 18+ · Women only
Bausch Health Americas, Inc. · Sites in United States
Ages 6–12
Karius, Inc. · Sites in United States
Ages 18+
NYU Langone Health · Sites in United States
Ages 18+
Baxis Pharmaceuticals, Inc. · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.
This study: Up to 3 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
181 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 67 · Phase 2 27 · Phase 3 24 · Phase 4 15
First in 1997; this study’s year is marked. 13 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 84 across 383 interventional studies indexed under Bacterial Infections.
Median enrollment 62 across the 151 interventional studies, 200 across the 29 observational. Of the 160 that completed or were terminated, 58 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
102 of 181 have an industry lead sponsor. The 10 most frequent:
Basilea Pharmaceutica is the lead sponsor of 60 studies on the registry; 7 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.
Basilea Pharmaceutica has 1 study filed under Bacterial Infections — fewer than ten, so there is no comparison to draw.
7 of the studies in Bacterial Infections with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07607470Nanopath, IncLarge Algorithm Setting and Validation Study | 2026-12 |
| NCT06070688The University of Texas Health Science Center, HoustonAn Adjunct Test Distinguishing Bacterial From Viral Etiology Improves Resource Utilization and Efficiency in the ED. | 2026-12-31 |
| NCT07285785Bausch Health Americas, Inc.Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea | 2027-04-20 |
| NCT05846399University of Missouri-ColumbiaCAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE) | 2027-07-01 |
| NCT07371429GlaxoSmithKlineA Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics | 2027-08-23 |
Add all 7 to your calendar (.ics) → With an account.
Among the 181 studies in Bacterial Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study characterized the pharmacokinetics and safety of a single dose of ceftobiprole in neonates and infants aged ≤ 3 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ceftobiprole medocaril is the water-soluble prodrug of ceftobiprole, an advanced-generation cephalosporin developed for intravenous administration. Ceftobiprole is characterized by potent, broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative pathogens.
Drug: Ceftobiprole medocaril
Ceftobiprole medocaril was administered as a single intravenous infusion, with a bodyweight-adjusted volume, at a constant rate over 4 hours. The ceftobiprole dose was 7.5 mg/kg, which corresponds to 10.0 mg ceftobiprole medocaril.
Also known as: ceftobiprole
Cmax
The maximum observed plasma concentration (Cmax)
Time frame: Blood samples for pharmacokinetic (PK) analysis were obtained pre-dose, and at 2, 4, 6, 8, and 12 hours after the start of dosing.
Tmax
The time of maximum observed plasma concentration (Tmax)
Time frame: Blood samples for PK analysis were obtained pre-dose, and at 2, 4, 6, 8, and 12 hours after the start of dosing.
AUC0-last
The area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC0-last)
Time frame: Blood samples for PK analysis were obtained pre-dose, and at 2, 4, 6, 8, and 12 hours after the start of dosing.
T>MIC of 4 mg/L
The duration of time after dose for which free-drug concentrations remained above a value of 4 mg/L (T\>MIC of 4 mg/L)
Time frame: Blood samples for PK analysis were obtained pre-dose, and at 2, 4, 6, 8, and 12 hours after the start of dosing.
| Milestone | Ceftobiprole ITT/Safety Population |
|---|---|
| Started | 15 |
| Completed | 15 |
| Not completed | 0 |
The maximum observed plasma concentration (Cmax)
| μg/mL | Ceftobiprole PK Population |
|---|---|
| Cmax | 11.2 (8.68 to 32.6) |
The time of maximum observed plasma concentration (Tmax)
| hours | Ceftobiprole PK Population |
|---|---|
| Tmax | 4.00 (4.00 to 4.00) |
The area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC0-last)
| μg•hours/mL | Ceftobiprole PK Population |
|---|---|
| AUC0-last | 60.6 (49.1 to 126.0) |
The duration of time after dose for which free-drug concentrations remained above a value of 4 mg/L (T\>MIC of 4 mg/L)
| hours | Ceftobiprole PK Population |
|---|---|
| T>MIC of 4 mg/L | 5.40 (3.77 to 8.13) |
Collected over After start of study drug administration through the follow-up visit at study Day 7±3, relevant worsening of a subject's status was to be recorded as an adverse event (AE).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ceftobiprole ITT/Safety Population | 0/15 (0%) | 2/15 (13.3%) | 4/15 (26.7%) |
| Event | Ceftobiprole ITT/Safety Population |
|---|---|
| Diaphragmatic herniaGastrointestinal disorders | 1/15 |
| Cerebral infarctionNervous system disorders | 1/15 |
| Event | Ceftobiprole ITT/Safety Population |
|---|---|
| Dermatitis diaperSkin and subcutaneous tissue disorders | 2/15 |
| Drug DependencePsychiatric disorders | 1/15 |
| ErythemaSkin and subcutaneous tissue disorders | 1/15 |
| Age, Categorical(Participants) | Ceftobiprole ITT/Safety Population |
|---|---|
| <=18 years | 15 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Age, Continuous(days) | Ceftobiprole ITT/Safety Population |
|---|---|
| Median | 13 (8 to 43) |
| Sex: Female, Male(Participants) | Ceftobiprole ITT/Safety Population |
|---|---|
| Female | 5 |
| Male | 10 |
| Race (NIH/OMB)(Participants) | Ceftobiprole ITT/Safety Population |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 1 |
| White | 13 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2016 to primary completion in Feb 2020, 39 months.
Results were first posted in Jan 2021, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ceftobiprole medocaril